Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004017 · ClinicalTrials.gov registry record · Phase 2
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
A Phase 2 study, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00004017 is a Phase 2 study that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00004017, a Phase 2 study, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors. PURPOSE: Phase II trial to study the effectiveness of radiolabeled monoclonal antibody in treating patients who have glioblastoma multiforme or anaplastic astrocytoma.
Interventions
- PROCEDURE conventional surgery
- RADIATION iodine I 131 monoclonal antibody TNT-1/B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2000-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004017
The ClinicalTrials.gov registry entry for NCT00004017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which conventional surgery is the first listed.
NCT00004017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004017 about?
NCT00004017 is a clinical study titled "Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors. PURPOSE: Phase II trial to study the effectiveness of radiolabeled monoclonal antibody i...
What is the current status of trial NCT00004017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2000-02.
What interventions are being tested in trial NCT00004017?
The interventions under investigation include: conventional surgery (PROCEDURE), iodine I 131 monoclonal antibody TNT-1/B (RADIATION).
Who is sponsoring clinical trial NCT00004017?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.